LINCOLNSHIRE, Ill. – October 11, 2011 (Investorideas.com newswire) – BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study ...
The post Biotech stocks News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Positive LibiGel® Safety Data Review in Phase III Program appeared first on Your Story.